<DOC>
	<DOCNO>NCT02643056</DOCNO>
	<brief_summary>Phase II , multicenter , open label , uncontrolled study evaluate efficacy safety profile panitumumab patient affected Head Neck cancer least one cisplatin carboplatin-based chemotherapy . A translational research study also plan evaluate EGFR status FISH , KRAS , B-RAF , HRAS , NRAS PIK3CA mutation DNA sequencing , PTEN protein expression immunohistochemistry , HPV genotyping reverse hybridization . Panitumumab administer iv day 1 15 28 day cycle , progressive disease , unacceptable toxicity , pregnancy , patient 's refusal</brief_summary>
	<brief_title>Study Investigate Efficacy Panitumumab Platinum-resistant Advanced Head Neck Squamous Cancer</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>ECOG performance status 02 , pregnant . Histologically cytologically confirm Squamous Cell Cancer Head Neck either metastatic recurrent , judge incurable surgery radiation . Baseline tumor tissue , sufficient material available EGFR determination ( therapeutic target panitumumab ) biomarker study . Patients without available tissue baseline tissue collect longer 1 year , may undergo tumor biopsy . Progression respond treatment least one cisplatin carboplatin contain regimen . Measurable disease ( RECIST 1.1 ) . Adequate hematological value , renal hepatic function . Patients may receive investigational agent Platinumna√Øve patient . Patients previously progress regimen contain EGFRinhibiting agent ( cetuximab , panitumumab , gefitinib , erlotinib ) , even initial response . Clinically significant cardiovascular disease ( include myocardial infarction , unstable angina , symptomatic congestive heart failure , serious uncontrolled cardiac arrhythmia ) 1 year enrollment/randomization . History interstitial lung disease e.g . pneumonitis pulmonary fibrosis evidence interstitial lung disease baseline chest CT scan . Known suspected brain metastasis . Psychiatric disorder preclude understanding information trial related topic , give informed consent Known hypersensitivity panitumumab active ingredient excipients . Any concomitant drug contraindicate use trial drug accord Swissmedic approve product information HIV positive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>